T
66.06
-2.26 (-3.31%)
| 前收盘价格 | 68.32 |
| 收盘价格 | 68.95 |
| 成交量 | 727,081 |
| 平均成交量 (3个月) | 688,018 |
| 市值 | 2,788,663,552 |
| 价格/销量 (P/S) | 7.91 |
| 股市价格/股市净资产 (P/B) | 7.46 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 营业毛利率 | -44.91% |
| 营业利益率 (TTM) | -33.55% |
| 稀释每股收益 (EPS TTM) | -2.70 |
| 季度收入增长率 (YOY) | 183.70% |
| 总债务/股东权益 (D/E MRQ) | 21.13% |
| 流动比率 (MRQ) | 5.57 |
| 营业现金流 (OCF TTM) | -65.89 M |
| 杠杆自由现金流 (LFCF TTM) | -36.41 M |
| 资产报酬率 (ROA TTM) | -16.05% |
| 股东权益报酬率 (ROE TTM) | -33.98% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Tarsus Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.6
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | -3.0 |
| 技术平均移动指标 | -5.0 |
| 技术振荡指标 | 4.0 |
| 平均 | -0.63 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.25% |
| 机构持股比例 | 110.77% |
| 52周波幅 | ||
| 中 | 88.00 (33.21%) | |
| 总计 | 1 购买 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Oct 2025 | 88.00 (33.21%) | 购买 | 71.19 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 27 Aug 2025 | 公告 | Tarsus to Participate in Upcoming Investor Conferences |
| 06 Aug 2025 | 公告 | Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements |
| 30 Jul 2025 | 公告 | Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合